Sander de Vos is a seasoned executive with more than 15 years of experience in commercial and business growth roles in the healthcare and biotech industries.
FREMONT, CA: IME Medical Electrospinning, a global leader in electrospun medical devices for tissue rebuilding and regenerative medicine, including implants and drug delivery solutions, announced Sander de Vos's addition to its management team Chief Business Officer (CBO). He will be in charge of the company's global medical electrospinning strategy, which will be focused on IME's groundbreaking MediSpin industrial production platform.
"We at IME are thrilled to welcome Sander to our fast-growing team of professionals. Sander clearly brings a wealth of well-needed life science experience into the company, that will certainly be of key value to the further development of our electrospun medical device franchises. Our aim is to become the first partner of choice worldwide for the development of a novel, groundbreaking class of medical devices and pharma products based on nanofibers. Our ever-growing portfolio of customers and partners includes the Medtech and Pharma industry, universities, hospitals and medical institutes," said Judith Heikoop, CEO, IME Medical Electrospinning.
Sander de Vos is a seasoned executive with more than 15 years of experience in commercial and business growth roles in the healthcare and biotech industries. Sander previously worked at Mimetas, an ambitious Dutch start-up that develops novel human cell biology models for improved therapies, where he was instrumental in expanding the company's partnerships with pharma and biotech firms.
"With the potential of becoming the global leader in large-scale production of best-in-class nanofiber based medical devices and drug delivery solutions. I’m proud, gratified and delighted to become a member of the IME management team. The company’s technology enables faster and better recovery of tissues and body structures, and therefore IME is uniquely positioned to make a meaningful difference in the lives of patients," said de Vos.
Sander previously led Isogen Life Science's commercial team and gained experience as an entrepreneur developing a private company. His commercial career began at Westburg Life Sciences, where he influenced and directed the sales strategy and commercial growth of a portion of the company's life science sector for more than ten years.Sander has a background in molecular biology. While at Utrecht University's Faculty of Veterinary Medicine, he co-developed a molecular diagnostic test for simultaneous detection of tick-borne pathogens and helped create a tick vaccine.